Teva Pharmaceutical Industries reported $4.4B in revenue (-1.9% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 11 open management expectations for this company. 6 insider sales recorded.
Ерік Г'юз, виконавчий віцепрезидент та головний медичний директор Teva Pharmaceutical Industries, 17 листопада 2026 року повідомив про відставку. Він негайно залишає свою посаду заради пропозиції в іншій компанії, але допомагатиме з передачею справ упродовж наступних кількох місяців.
Teva Pharmaceutical Industries Ltd. chief executive officer Richard D. Francis sold 250,000 company shares on November 10, 2026. The deal was executed under a Rule 10b5-1 trading plan, a preset selling schedule executives set up in advance.
Teva reported $4.4 billion in revenue for the third quarter of 2026, a 2% decrease compared to the same period in 2025. These results reflect changes in U.S. sales volumes and the performance of its innovative drug portfolio.
On September 14, 2026, Teva Pharmaceutical Industries Ltd began trading ordinary shares on the New York Stock Exchange under ticker TEVA, replacing American depositary shares (ADS) on a one-to-one basis
Teva Pharmaceutical Industries Ltd. appointed a new member to its Board of Directors in October 2026.
On October 27, 2026, the Board of Directors elected Dr. David J. Brailer to serve as a member of the Board, effective November 3, 2026, until Teva's 2027 annual meeting of shareholders.Source
Dr. David J. Brailer will receive the same compensation as Teva’s other non-executive directors.Source
September 2026
Teva subsidiaries issued multiple series of senior notes guaranteed by the company.
TPFN II issued €1,000,000,000 of 4.250% Senior Notes due 2033, guaranteed by Teva.Source
TPFN III issued $500,000,000 of 5.500% Senior Notes due 2034 and $500,000,000 of 5.750% Senior Notes due 2037, guaranteed by Teva.Source
TPFN IV issued $500,000,000 of 5.250% Senior Notes due 2032, $500,000,000 of 5.250% Senior Notes due 2032, and $200,000,000 of 5.250% Senior Notes due 2032.Source
The notes were registered under a registration statement filed on 7 February 2025.Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Key figures
From the 10-Q for the period ended September 30, 2026, filed November 3, 2026. SEC
Latest
Earlier
Change
Revenue quarter
$4.4B
$4.5B
-1.9%
Operating income quarter
$714M
$882M
-19.0%
Net income quarter
$233M
$433M
-46.2%
Diluted EPS quarter
$0.20
$0.37
-45.9%
Operating cash flow quarter
$241M
$369M
-34.7%
Cash and cash equivalents balance
$4.1B
$3.6B
+14.9%
Next results expected around February 2, 2027 (estimate: the quarter ending about December 30, 2026 plus the 34 days the last report took). The company announces the actual date.
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
Date
Event
Filing
October 29, 2026
Director or officer departure or appointment (8-K item 5.02)
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.